Literature DB >> 12186951

Normal timing of oligodendrocyte development from genetically engineered, lineage-selectable mouse ES cells.

Nathalie Billon1, Christine Jolicoeur, Qi Long Ying, Austin Smith, Martin Raff.   

Abstract

Oligodendrocytes are post-mitotic cells that myelinate axons in the vertebrate central nervous system (CNS). They develop from proliferating oligodendrocyte precursor cells (OPCs), which arise in germinal zones, migrate throughout the developing white matter and divide a limited number of times before they terminally differentiate. Thus far, it has been possible to purify OPCs only from the rat optic nerve, but the purified cells cannot be obtained in large enough numbers for conventional biochemical analyses. Moreover, the CNS stem cells that give rise to OPCs have not been purified, limiting one's ability to study the earliest stages of commitment to the oligodendrocyte lineage. Pluripotent, mouse embryonic stem (ES) cells can be propagated indefinitely in culture and induced to differentiate into various cell types. We have genetically engineered ES cells both to positively select neuroepithelial stem cells and to eliminate undifferentiated ES cells. We have then used combinations of known signal molecules to promote the development of OPCs from selected, ES-cell-derived, neuroepithelial cells. We show that the earliest stages of oligodendrocyte development follow an ordered sequence that is remarkably similar to that observed in vivo, suggesting that the ES-cell-derived neuroepithelial cells follow a normal developmental pathway to produce oligodendrocytes. These engineered ES cells thus provide a powerful system to study both the mechanisms that direct CNS stem cells down the oligodendrocyte pathway and those that influence subsequent oligodendrocyte differentiation. This strategy may also be useful for producing human cells for therapy and drug screening.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186951     DOI: 10.1242/jcs.00049

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  42 in total

Review 1.  Impact of induced pluripotent stem cells on the study of central nervous system disease.

Authors:  Paige E Cundiff; Stewart A Anderson
Journal:  Curr Opin Genet Dev       Date:  2011-01-27       Impact factor: 5.578

Review 2.  From stem cells to oligodendrocytes: prospects for brain therapy.

Authors:  Cui P Chen; Mary E Kiel; Dorota Sadowski; Randall D McKinnon
Journal:  Stem Cell Rev       Date:  2007-12       Impact factor: 5.739

3.  REST selectively represses a subset of RE1-containing neuronal genes in mouse embryonic stem cells.

Authors:  Helle F Jørgensen; Anna Terry; Chiara Beretta; C Filipe Pereira; Marion Leleu; Zhou-Feng Chen; Claire Kelly; Matthias Merkenschlager; Amanda G Fisher
Journal:  Development       Date:  2009-03       Impact factor: 6.868

4.  Is REST required for ESC pluripotency?

Authors:  Helle F Jørgensen; Zhou-Feng Chen; Matthias Merkenschlager; Amanda G Fisher
Journal:  Nature       Date:  2009-02-26       Impact factor: 49.962

5.  KRAB zinc-finger proteins localise to novel KAP1-containing foci that are adjacent to PML nuclear bodies.

Authors:  Stephanie Briers; Catherine Crawford; Wendy A Bickmore; Heidi G Sutherland
Journal:  J Cell Sci       Date:  2009-03-03       Impact factor: 5.285

6.  Naive-like conversion overcomes the limited differentiation capacity of induced pluripotent stem cells.

Authors:  Arata Honda; Masanori Hatori; Michiko Hirose; Chizumi Honda; Haruna Izu; Kimiko Inoue; Ryutaro Hirasawa; Shogo Matoba; Sumie Togayachi; Hiroyuki Miyoshi; Atsuo Ogura
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

7.  Generation and characterization of spiking and nonspiking oligodendroglial progenitor cells from embryonic stem cells.

Authors:  Peng Jiang; Chen Chen; Xiao-Bo Liu; Vimal Selvaraj; Wei Liu; Daniel H Feldman; Ying Liu; David E Pleasure; Ronald A Li; Wenbin Deng
Journal:  Stem Cells       Date:  2013-12       Impact factor: 6.277

8.  Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells.

Authors:  Shin-ichiro Ogawa; Yasuhito Tokumoto; Jun Miyake; Teruyuki Nagamune
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-06-22       Impact factor: 2.416

Review 9.  Cell therapy for multiple sclerosis.

Authors:  Tamir Ben-Hur
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

10.  Differentiation of human oligodendrocytes from pluripotent stem cells.

Authors:  Bao-Yang Hu; Zhong-Wei Du; Su-Chun Zhang
Journal:  Nat Protoc       Date:  2009-10-15       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.